共 69 条
[1]
Ferrari S(2007)Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma Curr Opin Oncol 19 341-346
[2]
Palmerini E(2002)Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J Clin Oncol 20 776-790
[3]
Bielack SS(2003)Pos t relapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival J Clin Oncol 21 710-715
[4]
Kempf-Bielack B(2014)Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii113-iii123
[5]
Delling G(1994)Synovial sarcoma. Uniform response of metastases to high dose ifosfamide Cancer 73 2506-2511
[6]
Ferrari S(1997)High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose–response and schedule dependence J Clin Oncol 15 2378-2384
[7]
Briccoli A(2012)A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma Eur J Cancer 48 564-570
[8]
Mercuri M(2012)A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study Ann Oncol 23 508-516
[9]
Rosen G(2015)Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial Lancet Oncol 16 98-107
[10]
Forscher C(2012)Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study) Oncologist 17 1213-1220